Literature DB >> 10799454

Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

M Nokta1, P Turk, K Loesch, R B Pollard.   

Abstract

The relationship of the neutralizing activity (NA) profile of sera from human immunodeficiency virus (HIV)-infected individuals to the HIV viral load and the absolute CD4 count was examined. The NA of 24 serum samples against autologous isolates (AI) and HIV type 1 strain MN was examined. Three NA patterns were recognized. Nine sera neutralized both AI and MN (+/+), six sera neutralized MN but not AI (-/+), and nine sera failed to neutralize both AI and MN (-/-). The identification of the three neutralization patterns (+/+, -/+, and -/-) indicated that resistance to neutralization was progressive. A reciprocal relationship between the viral burden of the patients and the NA profiles was observed. The nine subjects with a -/- NA profile had a plasma viral load of > or =5 x 10(4) copies/ml and a cellular viral burden of > or =1,122 infectious units per million viable cells, which were significantly different from those of the other groups (P < 0.02). These patterns were independent of the phenotypic characteristics of the virus. Longitudinally, subjects with a -/- profile at baseline gained their HIV-specific NA by 24 weeks of antiretroviral therapy when this was associated with a >/=1-log(10) decline in the plasma HIV viral load. The sera from week 24 from some patients were able to neutralize both the 24-week and the baseline dominant virus isolates. A change in CD4 cell count of 50 or more in either direction predicted a -/- or +/+ profile. The verification of the autologous NA profile might be important in selecting patients who may benefit from immune-based therapies involving neutralizing monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799454      PMCID: PMC95887          DOI: 10.1128/CDLI.7.3.412-416.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  29 in total

1.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

2.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

3.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

4.  Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations.

Authors:  P Balfe; P Simmonds; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution.

Authors:  T F Wolfs; G Zwart; M Bakker; M Valk; C L Kuiken; J Goudsmit
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

6.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

Authors:  P L Nara; L Smit; N Dunlop; W Hatch; M Merges; D Waters; J Kelliher; R C Gallo; P J Fischinger; J Goudsmit
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

10.  Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Authors:  A Trkola; T Ketas; V N Kewalramani; F Endorf; J M Binley; H Katinger; J Robinson; D R Littman; J P Moore
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.